Analystreport

Y-mAbs Therapeutics (NASDAQ: YMAB) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.

Y-mAbs Therapeutics, Inc.  (YMAB) 
Last y-mabs therapeutics, inc. earnings: 11/13 04:01 pm Check Earnings Report